<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24915420</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>09</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1873-2968</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>90</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical pharmacology</Title>
<ISOAbbreviation>Biochem. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Coordinate regulation between the nuclear receptor peroxisome proliferator-activated receptor-γ and cyclooxygenase-2 in renal epithelial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>432-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2014.06.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0006-2952(14)00332-3</ELocationID>
<Abstract>
<AbstractText>The peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors involved in lipid metabolism and glucose utilization, in cell growth, differentiation and apoptosis, and in the regulation of pro-inflammatory genes expression such as cyclooxygenase-2 (COX-2). PPARγ is the main isoform in the renal inner medulla where it is believed to possess nephroprotective actions. In this kidney zone, COX-2 acts as an osmoprotective gene and its expression is modulated by changes in interstitial osmolarity. In the present work we evaluated whether hyperosmolar-induced COX-2 expression is modulated by PPARγ in renal epithelial cells MDCK subjected to high NaCl medium. The results presented herein show that ligand-activated PPARγ repressed COX-2 expression. But more important, the present findings show that hyperosmolar medium decreased PPARγ protein and increases the PPARγ phosphorylated form, which is inactive. ERK1/2 and p38 activation precedes PPARγ disappearance and induced-COX-2 expression. Therefore, the decrease in PPARγ expression is required for hyperosmotic induction of COX-2. We also found that PGE2, the main product of COX-2 in MDCK cells, induced these changes in PPARγ protein. Our results may alert on the long term use of thiazolidinediones (TZD) since they could affect renal medullary function that depends on COX-2 for cellular protection against osmotic stress. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Casali</LastName>
<ForeName>Cecilia I</ForeName>
<Initials>CI</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, School of Pharmacy and Biochemistry, University of Buenos Aires Ciudad Autónoma de Buenos Aires C1113AAD, Argentina; IQUIFIB-CONICET, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Weber</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, School of Pharmacy and Biochemistry, University of Buenos Aires Ciudad Autónoma de Buenos Aires C1113AAD, Argentina; IQUIFIB-CONICET, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Faggionato</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, School of Pharmacy and Biochemistry, University of Buenos Aires Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gómez</LastName>
<ForeName>Emanuel Morel</ForeName>
<Initials>EM</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, School of Pharmacy and Biochemistry, University of Buenos Aires Ciudad Autónoma de Buenos Aires C1113AAD, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tome</LastName>
<ForeName>María C Fernández</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Department of Biological Sciences, School of Pharmacy and Biochemistry, University of Buenos Aires Ciudad Autónoma de Buenos Aires C1113AAD, Argentina; IQUIFIB-CONICET, Ciudad Autónoma de Buenos Aires C1113AAD, Argentina. Electronic address: fertome@ffyb.uba.ar.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2014</Year>
<Month>06</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Biochem Pharmacol</MedlineTA>
<NlmUniqueID>0101032</NlmUniqueID>
<ISSNLinking>0006-2952</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C097240">15-deoxy-delta(12,14)-prostaglandin J2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C457499">2-chloro-5-nitrobenzanilide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000813">Anilides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>05V02F2KDG</RegistryNumber>
<NameOfSubstance UI="D000077154">Rosiglitazone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>451W47IQ8X</RegistryNumber>
<NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.-</RegistryNumber>
<NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>K7Q1JQR04M</RegistryNumber>
<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>RXY07S6CZ2</RegistryNumber>
<NameOfSubstance UI="D015230">Prostaglandin D2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000813">Anilides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017931">DNA Primers</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004285">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004847">Epithelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D047495">PPAR gamma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015230">Prostaglandin D2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011494">Protein Kinases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077154">Rosiglitazone</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012965">Sodium Chloride</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045162">Thiazolidinediones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cyclooxygenase-2 (COX-2)</Keyword>
<Keyword MajorTopicYN="N">Hyperosmolarity</Keyword>
<Keyword MajorTopicYN="N">Nephroprotection</Keyword>
<Keyword MajorTopicYN="N">Peroxisome proliferator-activated receptor gamma (PPARγ)</Keyword>
<Keyword MajorTopicYN="N">Thiazolidinediones (TZD)</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>04</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2014</Year>
<Month>06</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>06</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>6</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24915420</ArticleId>
<ArticleId IdType="pii">S0006-2952(14)00332-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.bcp.2014.06.002</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>